Abstract Number: PB0078
Meeting: ISTH 2022 Congress
Theme: COVID and Coagulation » COVID and Coagulation, Clinical
Background: Thrombosis is a frequent and severe complication in COVID-19 patients admitted to the intensive care unit (ICU). Lupus anticoagulant (LA) is a strong acquired risk factor for thrombosis in various diseases and is frequently observed in COVID-19 patients. Whether LA is associated with thrombosis in patients with severe COVID-19 is currently unclear.
Aims: To investigate if LA is associated with thrombosis in critically ill COVID-19 patients.
Methods: The presence of LA and other antiphospholipid antibodies was assessed in COVID-19 patients admitted to the ICU. Informed consent was obtained by an opt-out approach and the study was approved by the local medical ethical committee. LA was determined with dilute Russell’s Viper Venom Time (dRVVT) and LA-sensitive Activated Partial Thromboplastin Time (aPTT) reagents. Statistical analysis to study the association of LA and other antiphospholipid antibodies with thrombosis occurrence was performed using logistic regression.
Results: Out of 169 COVID-19 patients, 116 (69%) tested positive for at least one antiphospholipid antibody upon admission to the ICU. Forty (24%) patients tested positive for LA; of whom 29 (17%) tested positive with a dRVVT, 19 (11%) tested positive with an LA-sensitive aPTT and eight (5%) tested positive on both tests. Fifty-eight (34%) patients developed thrombosis after ICU admission. The odds ratio (OR) for thrombosis in patients with LA based on a dRVVT was 2.4 (95%-CI: 1.1-5.4), which increased to 5.1 (95%-CI: 1.7-15.4) in patients on or below the median age of this study population (64 years). LA-positivity based on a dRVVT or LA-sensitive aPTT was only associated with thrombosis in patients younger than 65 years (OR: 4.2, 95%-CI: 1.5-11.7).
Conclusion(s): LA on admission is strongly associated with thrombosis in critically ill COVID-19 patients, especially in patients < 65 years of age.
To cite this abstract in AMA style:
Noordermeer T, Schutgens R, Visser C, Rademaker E, de Maat M, Jansen A, Limper M, Cremer O, Kruip M, Endeman H, Maas C, de Laat B, Urbanus R. Lupus anticoagulant as predictor for thrombosis in critically ill COVID-19 patients: a retrospective cohort study [abstract]. https://abstracts.isth.org/abstract/lupus-anticoagulant-as-predictor-for-thrombosis-in-critically-ill-covid-19-patients-a-retrospective-cohort-study/. Accessed April 17, 2024.« Back to ISTH 2022 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/lupus-anticoagulant-as-predictor-for-thrombosis-in-critically-ill-covid-19-patients-a-retrospective-cohort-study/